Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting
The cytochrome P450 2C9 and vitamin K epoxide reductase complex subunit 1 genotypes are associated with anticoagulation control and the clinical events in warfarin therapy. However, the clinical utility of gene-based warfarin dosing (GBWD) is controversial. We compared the anticoagulation control an...
Main Authors: | Jinhua Zhang, Tingting Wu, Wenjun Chen, Jinglan Fu, Xiaotong Xia, Liangwan Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01527/full |
Similar Items
-
The Effect of CYP2C9 and VKORC1 Genetic Polymorphism on Warfarin Dose Requirements in a Sample of Iraqi Patients
by: Maha Ali Saleh, et al.
Published: (2021-03-01) -
Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
by: Nita A Limdi, et al.
Published: (2012-10-01) -
Pharmacogenetics of warfarin: A literature review
by: Nadezhda V. Izmozherova, et al.
Published: (2024-11-01) -
Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population
by: T. A. Bairova, et al.
Published: (2019-07-01) -
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians
by: Utama Andi, et al.
Published: (2011-06-01)